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Abstract
Background: While the risk of severe complications of Middle East respiratory syndrome (MERS) and its determinants
have been explored in previous studies, a systematic analysis of published articles with different designs and
populations has yet to be conducted. The present study aimed to systematically review the risk of death
associated with MERS as well as risk factors for associated complications.
Methods: PubMed and Web of Science databases were searched for clinical and epidemiological studies on confirmed
cases of MERS. Eligible articles reported clinical outcomes, especially severe complications or death associated with
MERS. Risks of admission to intensive care unit (ICU), mechanical ventilation and death were estimated. Subsequently,
potential associations between MERS-associated death and age, sex, underlying medical conditions and study design
were explored.
Results: A total of 25 eligible articles were identified. The case fatality risk ranged from 14.5 to 100%, with the pooled
estimate at 39.1%. The risks of ICU admission and mechanical ventilation ranged from 44.4 to 100% and from 25.0 to
100%, with pooled estimates at 78.2 and 73.0%, respectively. These risks showed a substantial heterogeneity among the
identified studies, and appeared to be the highest in case studies focusing on ICU cases. We identified older age, male
sex and underlying medical conditions, including diabetes mellitus, renal disease, respiratory disease, heart disease and
hypertension, as clinical predictors of death associated with MERS. In ICU case studies, the expected odds ratios (OR) of
death among patients with underlying heart disease or renal disease to patients without such comorbidities were 0.6
(95% Confidence Interval (CI): 0.1, 4.3) and 0.6 (95% CI: 0.0, 2.1), respectively, while the ORs were 3.8 (95% CI: 3.4, 4.2) and
2.4 (95% CI: 2.0, 2.9), respectively, in studies with other types of designs.
Conclusions: The heterogeneity for the risk of death and severe manifestations was substantially high among the
studies, and varying study designs was one of the underlying reasons for this heterogeneity. A statistical estimation of
the risk of MERS death and identification of risk factors must be conducted, particularly considering the study design
and potential biases associated with case detection and diagnosis.
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Background
Cases of Middle East respiratory syndrome (MERS),
caused by MERS-associated coronavirus (MERS-CoV),
have continuously been reported since June 2012. As of
29 June 2016, the total number of laboratory-confirmed
cases notified to the World Health Organization (WHO)
reached 1,768 cases, including 630 deaths [1]. Particu-
larly large outbreaks of MERS-CoV infection have been
reported in the Kingdom of Saudi Arabia (KSA) and the
Republic of Korea (ROK), while smaller outbreaks and
importation events have been reported in other 25 coun-
tries [1]. Of these, 10 countries are located in the Middle
East, 7 countries in Europe, 3 countries in Africa, 3
countries in Southeast and East Asia, and 1 in North
America (the United States of America) [2–4]. Because
of the regular reporting of MERS cases in the Middle
East, countries across the world are now facing a
continuous threat of MERS outbreak.
To understand the clinical burden of MERS, it is ne-
cessary to quantify the risk of developing severe clinical
manifestations. The case fatality risk (CFR) is a measure
of the risk of death among those who satisfy the case
condition [5], while risks of admission to an intensive
care unit (ICU) and that of requiring mechanical ventila-
tion are also useful to measure the extent of developing
severe MERS complications. However, it is not only
necessary to estimate such risks, but it is also critically
important to identify epidemiological determinants of
those risks to then predict the risk of severe complica-
tions for each patient before the onset of disease exacer-
bation [6]. In previous studies, the risk of death among
secondary cases was estimated based on statistical mod-
elling and was found to range from 20 to 22%, approxi-
mately [7–11]. Meanwhile, among the primary cases, the
risk of death was estimated to be greater at approxi-
mately 40%, perhaps because of biases associated with
case detection and diagnosis [6–8]. As for epidemio-
logical determinants of MERS death, elderly patients
with underlying comorbidities have been identified as
the most susceptible population with a high risk of
death [6, 9, 11].
Despite our further understanding of the risk of devel-
oping severe MERS, the abovementioned estimates are
mostly based on a subset of MERS cases; for instance,
some of the risk estimates are a result of the analysis of
cases diagnosed in 2015 in the ROK or KSA alone.
Published articles with different study designs and popu-
lations have yielded different estimates and effect sizes
associated with MERS death. Because of this variability,
it is valuable to comprehensively and systematically
analyze published MERS studies that have recorded the
clinical prognoses of cases. A systematic review is a
highly informative review method that combines pub-
lished results from different studies, thereby merging
and contrasting results across multiple studies and an-
swering study questions using the pooled estimates [12].
Thus, we aimed to perform a systematic review to as-
sess risks of death and other severe complications
and determine the risk factors for MERS-associated
death and contrast these results by study population
and study design.
Methods
The present study was a systematic review conducted in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment [13]. PICO statement: Our study question is
focused on laboratory confirmed cases of MERS regard-
less of their treatment status, and thus, involves only
retrospective observational studies, measuring their risks
of admission to Intensive Care Unit (ICU) and death
and comparing those risks by age, gender and underlying
comorbidities.
Search strategy
Our systematic review protocol is summarized as
Additional file 1. Published studies that referred to the
clinical prognosis of MERS cases were retrieved from
MEDLINE (PubMed) and Web of Science electronic da-
tabases on 16 May 2016. The following search terms
were used in “All fields” to identify relevant published
articles:
1. “MERS” OR “middle east respiratory syndrome” OR
“novel coronavirus” OR “novel coronavirus 2012”
2. “sever*”OR “fatal*”OR “death” OR “mortalit*”
3. “hospitalization” OR “intensive care” OR “ICU”
4. 1 AND 2 AND 3
We limited the search to articles published between
April 2012 (i.e., after the first MERS case was reported)
and June 2016. Additional studies reporting associated
outcomes that were not identified by the abovemen-
tioned search strategy were manually retrieved by track-
ing the references of included articles (i.e., ancestry and
discordancy approach). We restricted ourselves to publi-
cations written in English.
Study selection
All titles identified by the abovementioned search strat-
egy were independently screened by two authors (RM
and HN). Abstracts of potentially relevant articles were
subsequently reviewed for eligibility, and if a description
of severe or lethal MERS was available, articles were
selected for closer examination of the full text. To be
eligible for inclusion, published studies were required to
meet the following characteristics: (i) studies focused on
patients infected with MERS-CoV and (ii) explicitly
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documenting clinical outcomes (i.e., prognosis) and
characteristics of both surviving and deceased patients.
Studies that allowed us to stratify the risk of severe or
fatal MERS by demographic or medical condition were
preferred, but this was not an essential inclusion criter-
ion. To calculate the risk of severe MERS or MERS
death, we excluded case reports that documented only
one or two cases (i.e., case reports with a sample size
n ≥ 3 were eligible).
Included studies were further classified into five
groups based on the study design and population stud-
ied: (i) case reports comprising published studies that
described the clinical course of individual patients in-
cluding mild cases; (ii) studies including only ICU cases
(hereafter referred to as ICU studies): case reports or
retrospective studies that reported outcomes of patients
admitted to the ICU only; (iii) hospital studies: retro-
spective or descriptive studies that aimed to document
the outbreak in a hospital or healthcare-associated facil-
ity; (iv) retrospective studies: published studies that
retrospectively analyzed the series of MERS cases that
were registered in the patient database or tracked
medical records; and (v) surveillance studies: published
studies that extracted data from a database of cases, sys-
tematically gathering epidemiological data, as coordi-
nated by a country or WHO.
Data extraction and analysis
The primary data extracted were the proportions of de-
ceased MERS patients, patients admitted to the ICU and
patients undergoing mechanical ventilation. All of these
outcomes were dealt with as dichotomous variables, and
thus, we calculated the 95% confidence interval (CI) for
each included study using the binomial distribution.
Whenever possible, we stratified the risk of death by age,
sex, underlying medical condition and study design. For
the analysis of the effect of each covariate on the out-
come, the odds ratio (OR) for death among those with
underlying conditions was calculated and compared with
those without comorbidities. Stratified analysis could not
have been made for the proportions of ICU admission
and mechanical ventilation because the dataset of such
covariates was not commonly available for these two
outcomes. We employed a fixed effects inverse variance
weighted model. Weighted means (i.e. pooled estimate)
of the abovementioned proportions and the OR for
death by each covariate were calculated using the in-
verse of variance estimates from each study. The het-
erogeneity among identified studies was statistically
assessed by the I2 statistic. To explore the possible
sources of heterogeneity, we stratified pooled estimates
by study design. A forest plot was used to illustrate the
distribution of the outcome and effect size obtained
from each published study.
Results
The flow diagram of the search and study selection
process is shown in Fig. 1. Among a total of 599 poten-
tially relevant articles, 575 and 13 articles were excluded
by screening of the titles and abstracts, respectively. One
article was excluded by full-text screening. Following the
same process for 23 additional manually identified
articles, a total of 25 articles were selected as eligible ar-
ticles [8, 14–37] and all were subject to meta-analysis.
Of these, four studies were classified as case reports,
four as reports of ICU cases, four as hospital outbreak
studies, eight as retrospective studies and five as surveil-
lance study. The majority of included articles were
reported either from the KSA or the ROK, except for
one study conducted in Jordan [22] and the WHO
Fig. 1 Flow diagram of study selection
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MERS-CoV Research Group that combined reports from
multiple countries.
The estimated CFR was reported in 25 articles, ranging
from 14.5 to 100% (Fig. 2). The pooled CFR was 39.1%
(95% CI: 37.2, 41.1), but the I2 was as large as 92.4%. The
sample size of case reports ranged from 3 to 12, while
studies with other designs tended to have larger samples,
with 10 or more cases, except for one ICU study, one
retrospective study and one hospital outbreak study. The
proportions of ICU admission and mechanical ventilation
among all cases were available in 12 and 16 articles, respect-
ively. The proportion of ICU admission ranged from 44.4 to
100% with the pooled estimate at 78.2% (95% CI: 73.5, 82.9)
and an I2 value of 78.2%. The proportion of mechanical
ventilation ranged from 25.0 to 100% with the pooled esti-
mate at 73.0% (95% CI: 68.5, 77.5) and an I2 value of 68.0%.
Fig. 2 Estimated risks associated with Middle East respiratory syndrome (MERS) by published study. Panels show the risk estimates by study
outcome: (a) risk of death, (b) risk of admission to the intensive care unit (ICU) and (c) risk of requiring mechanical ventilation. CFR represents the
case fatality risk. The size of the diamonds reflects the sample size, and the whiskers extend to the lower and upper values of the 95% confidence
interval (CI). The diamond without fill represents the pooled estimate using the inverse variance of the risk of death. I2 measures the extent of the
heterogeneity, representing the proportion of variance in a meta-analysis that is attributable to study heterogeneity. Khalid et al., 2015a is [16]
while Khalid et al., 2015b is [19]
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Age and sex distributions are shown in relation to the
risk of death by MERS in Fig. 3. In the majority of the
studies (except for a study from Jordan), survivors were
younger than those who died of MERS. Although not gen-
erally, infected men tended to die more often than
women, and the pooled OR of death among men com-
pared with women was 1.4 (95% CI: 1.1, 1.6). The I2 value
of the sex difference for the risk of death was 48.6%.
The risks of death, ICU admission and mechanical
ventilation were stratified by study design and are shown
in Fig. 4, in which the pooled estimate for each study de-
sign was compared. The risk of death in the hospital
outbreak and surveillance studies was significantly
smaller than in ICU case and retrospective studies. Risks
of ICU admission and mechanical ventilation were the
highest among ICU case studies, followed by case report
and retrospective studies. Hospital outbreak studies
yielded the smallest pooled risks of ICU admission and
mechanical ventilation. When comparing surveillance-
based data between KSA and ROK (Fig. 2), the risk of
death in ROK (i.e., 14.5–22.0% [8, 33, 34]) tended to be
lower than that in KSA (i.e., 46.0% by Alsahafi and
Cheng [35]), perhaps reflecting the presence of the con-
tact tracing effort in the ROK.
Figure 5 shows the possible association between five
selected underlying medical conditions and the risk of
death by MERS. Pooled estimates of the OR were greater
than the value of 1 for all five comorbidities, including
diabetes mellitus (n = 8 studies), renal disease (6 studies),
respiratory disease (5 studies), heart disease (5 studies)
and hypertension (5 studies). Among a total of five pre-
dictors, heart disease yielded the greatest OR value at
3.5 (95% CI: 3.1, 4.8) followed by respiratory disease with
an OR of 3.1 (95% CI: 2.6, 4.2).
Figure 6 shows the potential association between the
risk of death by MERS and potential predictors, includ-
ing sex, heart disease and renal disease. Men from ICU
studies tended to yield a greater OR for death compared
with other study designs. Conversely, expected values of
ORs for death among those with heart disease and renal
disease compared with those without appeared to be
lower than the value of 1.0.
Discussion
The present study systematically reviewed the risk of
severe manifestations and death by MERS by systematic-
ally searching and analyzing published articles from the
KSA and the ROK and calculating not only the CFR but
Fig. 3 Age and sex distributions related to MERS-associated death by published study. a Ages of patients that survived and died of Middle East
respiratory syndrome (MERS) are compared. The range represents the minimum and maximum age. b Odds ratio (OR) of MERS death among
men compared with women. The size of the diamonds reflects the sample size, and the whiskers extend to the lower and upper values of the
95% confidence interval (CI). The vertical dashed line shows the threshold value of OR = 1. The diamond without fill represents the pooled
estimate using the inverse variance of OR. Khalid et al., 2015a is [16]. ICU represents intensive care unit
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also the risks of ICU admission and requiring mechan-
ical ventilation. Several clinical predictors of death were
identified including older age, male sex and underlying
medical conditions, including diabetes mellitus, renal
disease, respiratory disease, heart disease and hyperten-
sion. The risk estimate appeared to vary by study design.
In particular, studies focusing on patients in the ICU
yielded the greatest estimates, while the CFRs for sur-
veillance and hospital outbreak studies were smaller.
These findings indicate that ascertainment biases in
surveillance and hospital outbreak studies, frequently in-
volving case finding effort, were smaller than in other
types of studies. The importance of case finding effort is
likely reflected in the different CFR estimates based on
surveillance data between KSA and ROK. Although the
presently identified clinical predictors are in line with
previously published studies [6, 7, 11], the present study
is the first to systematically analyze published studies,
including clinical research studies, and extract findings
that echo those of published articles. As was observed in
this study, systematic search and analysis of the trans-
mission characteristics [38] and spatial spreading pat-
terns of MERS [39] have been successful.
An important contribution of the present study is that
we demonstrated that the risk of death or severe mani-
festations is highly heterogeneous for various reasons,
including different study designs. It is recognized that
MERS involves asymptomatic infection [9], and thus,
studies must be clear as to how the risk is estimated,
including the definition and diagnostic methods used to
identify infected individuals. Depending on the study de-
sign, the clinical predictors of death also differed. For
Fig. 4 Estimated risks associated with Middle East respiratory syndrome (MERS) by study design. Panels show the risk estimates by study outcome:
(a) risk of death, (b) risk of admission to intensive care unit (ICU) and (c) risk of mechanical ventilation. CFR represents the case fatality risk. The estimate
for each study design represents the pooled risk of death calculated using the inverse variance of the risk of death in each published study. The size
of the diamonds reflects the sample size, and the whiskers extend to the lower and upper values of the 95% confidence interval (CI). The diamond
without fill represents the pooled estimate using the inverse variance of the risk of death. I2 measures the extent of the heterogeneity, representing
the proportion of variance in a meta-analysis that is attributable to study heterogeneity
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example, renal and heart diseases might not predict the
risk of death in an ICU setting, but they may be critically
important in other settings that involve milder cases.
Not only studies in ICU settings, but also retrospective
studies yielded relatively high risk estimates for severe
manifestations and death. Our finding raises concerns
regarding the retrospective analysis of confirmed cases
in registered databases without referring to biases as-
sociated with case detection and diagnosis, which
could yield a biased risk estimate of MERS severity.
In fact, that could explain why the CFR of confirmed
cases among registered cases in patients’ database has
been as high as 40%, while the CFR of secondary
cases in the presence of contact tracing has been esti-
mated at about 20% [6–10].
The comorbidities identified in our study are in line
with those already identified elsewhere [6, 37]. The iden-
tification of comorbidities is not only stressed based on
previous and present findings [11], but it is critically
important to understand the underlying pathophysio-
logical mechanisms. High representation of men among
deceased cases may reflect the interaction of factors re-
lated to sex-specific lifestyle (e.g., smoking habits in the
Middle East). Older age might reflect the greater likeli-
hood of having underlying medical conditions. Diabetes,
renal and respiratory diseases could predispose patients
to be immunologically vulnerable and heart disease
could induce water retention (e.g., secondary aldosteron-
ism), both exacerbating the systemic condition. Hyper-
tension could have been confounded by some other
explanatory factor (s), for example, obesity could have
likely led to both hypertension and MERS death. Never-
theless, identified predictors are accompanied by reason-
able biological explanations.
The present study is not free from limitations. The
biggest concern is, given the absence of identifying infor-
mation, the included articles most likely referred to the
same cases multiple times, potentially overestimating the
Fig. 5 Risk of death by Middle East respiratory syndrome (MERS) by underlying medical condition. Panels a, b, c, d, and e show the risk estimates
by underlying medical condition. The odds ratio (OR) for MERS death to compare those with underlying conditions against those without
underlying conditions was calculated. The size of the diamonds reflects the sample size, and the whiskers extend to the lower and upper values
of the 95% confidence interval (CI). The vertical dashed line shows the threshold value of OR = 1. The diamond without fill represents the pooled
estimate using the inverse variance of the OR. I2 measures the extent of heterogeneity, representing the proportion of variance in a meta-analysis
that is attributable to study heterogeneity
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number of cases. In fact, the total number of diagnosed
and reported cases of MERS as of June 2016 is approxi-
mately 1,768 cases, but our systematic review included
as many as 2,081 cases. Thus, it is likely that multiple re-
ports from ROK (e.g., Cowling et al. [8], KCDCP [33]
and Majumder et al. [34]) reported on the same cases
multiple times. Rather, we did not avoid any overlap of
cases in datasets because that adjustment forced us to
adjust the overlap among the cases from the KSA in a
similar manner. For this reason, the pooled estimate
would never represent the actual pooled outcome data
because the same case was counted multiple times. If we
remove Cowling et al. [8] and Majumder et al. [34] from
our analysis and include KCDCP [33], which had the
largest sample size, the pooled estimate of the CFR
would be increased to 45.4% (95% CI: 43.2, 47.7). This is
understandable owing to the diminished impact of the
extensive contact tracing effort in the ROK. Despite
these overlaps, we conducted this systematic review to
demonstrate that ascertainment biases likely act as a key
factor that characterizes differential mortality across
countries. To avoid any overlap of cases and better
identify risk factors of ICU admission and death, it is
advised to set up a common case registration system
across countries and allocate identity number for each
individual case.
As the second technical limitation to remember, it
should be noted that the access to individual data was
not achieved, and thus, for instance the age-related ana-
lysis did not rest on individual age data, and similarly,
we have had limitations in the precision of the majority
of outcome evaluations. Third, clinical predictors of
death have been classified only at organ level, and more-
over, individual behavioral factors or habitat [40] have
not been examined in relation to the risk of MERS
death. Fourth, non-English language manuscripts have
been missed, and they include at least a few publications
in Korea and one from Jordan.
Despite these problems, we cannot help but consider
that the present study successfully and systematically
Fig. 6 Risk factors of death by Middle East respiratory syndrome (MERS) by study design. Panels show the risk estimates by covariate: (a) sex, (b): heart
disease and (c): renal disease). Odds ratio (OR) represents the odds ratio of death among men with underlying medical condition compared with women
without comorbidities, respectively. The size of the diamonds reflects the sample size, and the whiskers extend to the lower and upper values of the 95%
confidence interval (CI). The diamond without fill represents the pooled estimate using the inverse variance of the risk of death. I2 measures the extent of
heterogeneity, representing the proportion of variance in a meta-analysis that is attributable to study heterogeneity
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evaluated the risk of severe manifestations and death by
MERS by collecting published information on clinical
predictors of the risk of death. An important consider-
ation is that the associated risk estimation and identifica-
tion of risk factors of MERS call for particular care in
terms of study design, especially in aiming to eliminate
biases associated with detection and diagnosis.
Conclusions
Heterogeneity in risks of death and severe manifestations
secondary to MERS was substantial. Differential study
design was one of underlying reasons for the large hetero-
geneity. Statistical estimation of the risk of MERS death
and identification of risk factors must be conducted with
particular careful attention paid to study design, especially
accounting for biases associated with case detection and
diagnosis.
Additional file
Additional file 1: Systematic review protocol. Summary of systematic
review protocol is enumerated as a table. (DOCX 14 kb)
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